The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, speaks on the Phase II CLL2-GIVe trial (NCT02758665), which found promising safety and efficacy results for the triplet combination of obinutuzumab, ibrutinib, and venetoclax in patients with previously untreated high-risk chronic lymphocytic leukemia (CLL) with del(17p) and/or TP53 mutation. Following this, the Phase III CLL13 trial (NCT02950051) showed the superiority of this triplet regimen over doublet therapy in patients with unmutated IGHV. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Honoraria: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Travel support: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Research Funding: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca.
